We provide you with 20 years of free, institutional-grade data for NLTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NLTX. Explore the full financial landscape of NLTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Neoleukin Therapeutics, Inc(NASDAQ:NLTX) 
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines inte...
Website: http://www.neoleukin.com
Full Time Employees: 65
CEO: Jonathan G. Drachman
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Share this website to your friends
The information provided in this report about NLTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.